X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of agreement, Lonza will provide kilogram-scale synthesis, purification, and stability testing of Cantrixil, and deliver cGMP batches of drug substance for clinical supply. Oasmia will leverage Lonza’s extensive experience in manufacturing highly-potent API.
Lead Product(s): Cantrixil
Therapeutic Area: Oncology Product Name: TRX-E-002-1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lonza Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 21, 2022
Details:
Oasmia will assume worldwide exclusive rights to develop and commercialise Cantrixil for all indications, with an initial focus on ovarian cancer.
Lead Product(s): Cantrixil
Therapeutic Area: Oncology Product Name: TRE-E-002-1
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Kazia Therapeutics
Deal Size: $46.0 million Upfront Cash: $4.0 million
Deal Type: Licensing Agreement March 01, 2021
Details:
SAKK is the legal sponsor of the project and responsible to conduct the phase 1B trial. Oasmia’s main role in the project is to supply its formulation of docetaxel and carry the cost of the trial, which are deemed not material to Oasmia.
Lead Product(s): Docetaxel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: SAKK
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 08, 2020
Details:
Data collected from the Company’s development program of docecal, a solvent-free nanoparticle micellar formulation of docetaxel have been accepted for a poster presentation at the American Society of Clinical Oncology (ASCO) 2020.
Lead Product(s): Docetaxel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
Details:
As a result of the review, Oasmia decided to continue the development of Oasmia’s existing pipeline of XR17-based products, including Docecal (docetaxel) in breast and prostate cancers and its combination cancer therapy XR19.
Lead Product(s): Docetaxel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2020
Details:
The global strategic partnership deal is signed regarding the commercialization of Oasmia’s anticancer product Apealea®.
Lead Product(s): Paclitaxel,Carboplatin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Elevar Therapeutics
Deal Size: $698.0 million Upfront Cash: $20.0 million
Deal Type: Partnership April 21, 2020
Details:
The partnership between Oasmia and Elevar grants Elevar the exclusive right to commercialize Apealea®, in all global territories, except countries in which Oasmia and its partners are already present.
Lead Product(s): Paclitaxel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Elevar Therapeutics
Deal Size: Undisclosed Upfront Cash: $20.0 million
Deal Type: Partnership March 26, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
